Last reviewed · How we verify

NCT04266834

Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization

Completed NA Last updated 16 September 2020
What this trial tests

NA trial testing Experimental Arm in AKI in 157 participants. Completed in 30 June 2020.

Timeline
1 December 2019
Primary endpoint
1 June 2020
30 June 2020

Quick facts

Lead sponsorQure Healthcare, LLC
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment157
Start date1 December 2019
Primary completion1 June 2020
Estimated completion30 June 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Qure Healthcare, LLC — full company profile →

Who can join

Eligibility, any sex, with AKI or Contrast-induced Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will collect high-quality randomized controlled data across the U.S. from practicing cardiologists performing invasive/interventional procedures and determine how they currently manage patients at risk for CIN and how the results of Hikari's L-FABP test change clinical decision making.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Experimental Arm

Trials testing the same drug.

Other recruiting trials for AKI

Currently open trials in the same condition.

Other Qure Healthcare, LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04266834.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing